Step by Stepa HemeOncBuddy patient portal

Idarubicin

Illustration: Idarubicin

Say it: eye-duh-ROO-bih-sin · Brand names: Idamycin PFS

Idarubicin is a chemotherapy medicine that damages the genes of leukemia cells so they cannot grow.

What it is

Idarubicin slips into the genetic code (DNA) of the cell. It blocks a protein the cell needs to copy its DNA. The leukemia cell cannot divide and dies.

Often used for

How you get it

Idarubicin is given through a vein (IV), usually in the hospital. It takes about 10 to 15 minutes. It is often given once a day for 3 days, along with another chemotherapy called cytarabine. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

Questions to ask

Part of these treatment plans

Side effect guides

Sources

Quick answers

What is Idarubicin?
Idarubicin is a chemotherapy medicine that damages the genes of leukemia cells so they cannot grow. Brand names: Idamycin PFS.
What is Idarubicin used for?
acute myeloid leukemia in adults.
How is Idarubicin given?
Idarubicin is given through a vein (IV), usually in the hospital. It takes about 10 to 15 minutes. It is often given once a day for 3 days, along with another chemotherapy called cytarabine. Your schedule may be different.
What are the common side effects of Idarubicin?
Very low blood counts for a few weeks. Hair loss. Upset stomach or throwing up. Mouth sores. Diarrhea. Red or pink pee for a day or two.
When should I call my care team while taking Idarubicin?
A fever of 100.4 degrees Fahrenheit (38 degrees Celsius) or higher; Chills, a sore throat, a cough, or burning when you pee (signs of infection); Bleeding or bruising that is unusual for you; Shortness of breath, swelling in your legs or feet, or a fast or uneven heartbeat; Pain, redness, swelling, or burning where the IV went in; Throwing up or diarrhea so bad you cannot keep fluids down.
Which chemotherapy plans include Idarubicin?
FLAG-IDA.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.